FabRx has developed the world’s first GMP 3D printer for the production of personalised medicines, the M3DIMAKER™.
Our proprietary PRINTLETS™️ technology platform is suitable for most oral dosage forms and is specifically designed for the production of personalised medicines.
-Software for 3D printing (design, printing process control, quality asssurance, ...).
-AI driven software for formulations development (M3DISEEN). Machine learning algorithms to help researchers with new formulations.
Using our proprietary Printlets™ technology, we can create a range of personalised medicines, composed of specific dosages, API combinations, shapes, sizes and release profiles.
FabRx is involved in a number of projects with research organisations, universities and pharmaceutical companies to develop novel dosage forms using 3D printing. Our world-class team are experts in the field of pharmaceutical formulation and use our industry-leading technology platforms to develop next-generation dosage forms. From chewable, flavoured formulations for paediatric patients to multi-drug polyprintlets, FabRx is able to produce novel dosage forms that traditional manufacturing cannot.
Below is a pipeline of our current projects in a variety of disease and therapeutics areas. Get in contact to discuss how your formulation or research plans can benefit from the versatility of 3D printing.
Oncology
Rare diseases
Metabolic Disorders
Transplants
Nutraceuticals
Undisclosed Partner A1
Undisclosed Partner A2
Undisclosed Partner B1
Undisclosed Partner B2
Copyright © 2021 FabRx Ltd
